However, a proportion of patients with prostate cancer who are treated with CAB experience prostate-specific antigen (PSA) recurrence and are diagnosed as CRPC after confirming for anti-androgen withdrawal syndrome (AWS). Here, KLK3 is linked to prostate carcinoma.